Related Experiment Video
Updated: Aug 6, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Molecular determinants of irinotecan efficacy
Daniel Vallböhmer1, Syma Iqbal, Dong Yun Yang
1Divison of Medical Oncology, USC/Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, 90033, USA.
International Journal of Cancer
|August 9, 2006
Summary
Predicting colorectal cancer (CRC) treatment response is crucial. This study found that high mRNA levels of EGFR, ERCC1, and GST-P1 in tumors may predict patient response to CPT-11 chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Predictive molecular markers for CPT-11 chemotherapy in colorectal cancer (CRC) are currently unknown.
- Understanding these markers can optimize treatment strategies for metastatic CRC patients.
Purpose of the Study:
- To investigate the association between intratumoral mRNA levels of specific genes and the clinical outcome of patients with metastatic CRC treated with first-line CPT-11 based chemotherapy.
- To identify potential biomarkers for predicting treatment response and progression-free survival.
Main Methods:
- Retrospective analysis of 33 metastatic CRC patients.
- Assessment of intratumoral gene expression levels (Topoisomerase I, TS, DPD, EGFR, IL-8, VEGF, ERCC1, GST-P1) using laser capture microdissection and quantitative Real-Time PCR.
- Correlation of gene expression with treatment response (complete/partial response vs. stable/progressive disease) and progression-free survival.
Main Results:
- High intratumoral mRNA levels of Epidermal Growth Factor Receptor (EGFR), Excision Repair Cross-Complementation group 1 (ERCC1), and Glutathione S-transferase P1 (GST-P1) were significantly associated with response to CPT-11 chemotherapy.
- EGFR and ERCC1 mRNA levels were identified as key predictors distinguishing responders from non-responders.
- High expression of both EGFR and ERCC1 correlated significantly with improved progression-free survival.
- EGFR mRNA levels showed significant correlation with ERCC1, GST-P1, and VEGF expression.
Conclusions:
- Intratumoral gene expression levels of EGFR, ERCC1, and GST-P1 may serve as useful predictive biomarkers for clinical outcomes in metastatic CRC patients receiving first-line CPT-11 based chemotherapy.
- Further validation in larger prospective studies is warranted to confirm these findings and their clinical utility.
Related Concept Videos
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...